Quince Therapeutics, Inc. Operating Expenses
Quince Therapeutics, Inc. (QNCX) reported Operating Expenses of $79.78 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-14
- Quince Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $79.78M, a 665.15% increase year-over-year.
- Quince Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $14.59M, a 1.80% decline year-over-year.
- Quince Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $19.35M, a 61.11% increase year-over-year.
- Quince Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $13.43M, a 129.06% increase year-over-year.
- Quince Therapeutics, Inc. operating expenses for fiscal 2025 was $58.07M, a 1.37% increase from fiscal 2024.
- Quince Therapeutics, Inc. operating expenses for fiscal 2024 was $57.28M, a 65.47% increase from fiscal 2023.
- Quince Therapeutics, Inc. operating expenses for fiscal 2023 was $34.62M, a 33.44% decline from fiscal 2022.
- Quince Therapeutics, Inc. operating expenses for fiscal 2022 was $52.02M, a 42.41% decline from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $79.78M 10-Q · filed 2026-08-14 | $94.37M 10-Q · filed 2026-08-14 | $113.72M derived: sum of 3 quarters · filed 2026-08-14 | $127.16M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $14.59M 10-Q · filed 2026-05-11 | $33.94M derived: sum of 2 quarters · filed 2026-05-11 | $47.37M derived: sum of 3 quarters · filed 2026-05-11 | $57.80M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $19.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $32.78M derived: sum of 2 quarters · filed 2026-04-10 | $43.21M derived: sum of 3 quarters · filed 2026-08-14 | $58.07M 10-K · filed 2026-04-10 |
| 2025-09-30 | $13.43M 10-Q · filed 2025-11-12 | $23.86M derived: sum of 2 quarters · filed 2026-08-14 | $38.72M 10-Q · filed 2025-11-12 | $50.73M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $10.43M 10-Q · filed 2026-08-14 | $25.29M 10-Q · filed 2026-08-14 | $37.30M derived: sum of 3 quarters · filed 2026-08-14 | $43.16M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $14.86M 10-Q · filed 2026-05-11 | $26.87M derived: sum of 2 quarters · filed 2026-05-11 | $32.73M derived: sum of 3 quarters · filed 2026-05-11 | $60.92M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $12.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $17.88M derived: sum of 2 quarters · filed 2026-04-10 | $46.07M derived: sum of 3 quarters · filed 2026-04-10 | $57.28M 10-K · filed 2026-04-10 |
| 2024-09-30 | $5.86M 10-Q · filed 2025-11-12 | $34.05M derived: sum of 2 quarters · filed 2025-11-12 | $45.27M 10-Q · filed 2025-11-12 | $55.19M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $28.19M 10-Q · filed 2025-08-11 | $39.41M 10-Q · filed 2025-08-11 | $49.33M derived: sum of 3 quarters · filed 2025-08-11 | $55.42M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $11.22M 10-Q · filed 2025-05-13 | $21.14M derived: sum of 2 quarters · filed 2025-05-13 | $27.23M derived: sum of 3 quarters · filed 2025-05-13 | $32.82M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $9.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $16.02M derived: sum of 2 quarters · filed 2025-03-24 | $21.60M derived: sum of 3 quarters · filed 2025-03-24 | $34.62M 10-K · filed 2025-03-24 |
| 2023-09-30 | $6.09M 10-Q · filed 2024-11-13 | $11.68M derived: sum of 2 quarters · filed 2024-11-13 | $24.70M 10-Q · filed 2024-11-13 | $30.95M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $5.58M 10-Q · filed 2024-08-13 | $18.54M 10-Q · filed 2024-08-13 | $24.86M derived: sum of 3 quarters · filed 2024-08-13 | $32.48M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $12.96M 10-Q · filed 2024-05-13 | $19.27M derived: sum of 2 quarters · filed 2024-05-13 | $26.89M derived: sum of 3 quarters · filed 2024-05-13 | $43.15M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $6.32M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $13.94M derived: sum of 2 quarters · filed 2024-04-01 | $30.20M derived: sum of 3 quarters · filed 2024-04-01 | $52.02M 10-K · filed 2024-04-01 |
| 2022-09-30 | $7.62M 10-Q · filed 2023-11-14 | $23.88M derived: sum of 2 quarters · filed 2023-11-14 | $45.70M 10-Q · filed 2023-11-14 | $69.28M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $16.26M 10-Q · filed 2023-08-03 | $38.08M 10-Q · filed 2023-08-03 | $61.66M derived: sum of 3 quarters · filed 2023-08-03 | $83.34M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $21.86M 10-Q · filed 2023-05-15 | $45.41M derived: sum of 2 quarters · filed 2023-05-15 | $67.08M derived: sum of 3 quarters · filed 2023-05-15 | $88.87M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $23.54M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $45.22M derived: sum of 2 quarters · filed 2023-03-15 | $67.00M derived: sum of 3 quarters · filed 2023-03-15 | $90.32M 10-K · filed 2023-03-15 |
| 2021-09-30 | $21.68M 10-Q · filed 2022-11-09 | $43.46M derived: sum of 2 quarters · filed 2022-11-09 | $66.77M 10-Q · filed 2022-11-09 | $87.63M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $21.78M 10-Q · filed 2022-08-09 | $45.10M 10-Q · filed 2022-08-09 | $65.95M derived: sum of 3 quarters · filed 2022-08-09 | $87.86M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $23.31M 10-Q · filed 2022-05-10 | $44.16M derived: sum of 2 quarters · filed 2022-05-10 | $66.08M derived: sum of 3 quarters · filed 2022-05-10 | $84.35M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $20.85M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $42.76M derived: sum of 2 quarters · filed 2022-03-01 | $61.03M derived: sum of 3 quarters · filed 2022-03-01 | $78.89M 10-K · filed 2022-03-01 |
| 2020-09-30 | $21.91M 10-Q · filed 2021-10-29 | $40.18M derived: sum of 2 quarters · filed 2021-10-29 | $58.04M 10-Q · filed 2021-10-29 | $70.99M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $18.27M 10-Q · filed 2021-08-06 | $36.13M 10-Q · filed 2021-08-06 | $49.08M derived: sum of 3 quarters · filed 2022-03-01 | $59.65M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $17.86M 10-Q · filed 2021-05-06 | $30.81M derived: sum of 2 quarters · filed 2022-03-01 | $41.38M derived: sum of 3 quarters · filed 2022-03-01 | $50.95M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $12.95M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $23.52M derived: sum of 2 quarters · filed 2022-03-01 | $33.09M derived: sum of 3 quarters · filed 2022-03-01 | $39.17M 10-K · filed 2022-03-01 |
| 2019-09-30 | $10.57M 10-Q · filed 2020-11-12 | $20.14M derived: sum of 2 quarters · filed 2020-11-12 | $26.22M 10-Q · filed 2020-11-12 | $30.06M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $9.57M 10-Q · filed 2020-08-14 | $15.65M 10-Q · filed 2020-08-14 | $19.49M derived: sum of 3 quarters · filed 2021-03-01 | $22.37M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $6.08M 10-Q · filed 2020-05-12 | $9.92M derived: sum of 2 quarters · filed 2021-03-01 | $12.79M derived: sum of 3 quarters · filed 2021-03-01 | $15.43M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $3.84M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $6.72M derived: sum of 2 quarters · filed 2021-03-01 | $9.36M derived: sum of 3 quarters · filed 2021-03-01 | $12.12M 10-K · filed 2021-03-01 |
| 2018-09-30 | $2.87M 10-Q · filed 2019-11-12 | $5.52M derived: sum of 2 quarters · filed 2019-11-12 | $8.28M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $2.64M 10-Q · filed 2019-08-09 | $5.40M 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | $2.76M 10-Q · filed 2019-06-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |